Sign in
VRDN Stock Price, Chart, Stats & News
Viridian Therapeutics, Inc.
Save
1.59B
Market cap
–
Current P/E
1.01x
Forward P/E
VRDN chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 99.55% |
Operating margin | -512.91% |
Pretax margin | -483.57% |
Net margin | -483.57% |
Effective tax rate | – |
ROA | -38.09% |
ROE | -58.44% |
D/E | 0.07x |
Interest coverage ratio | -43.95x |
VRDN valuation
P/E | – |
P/S | 32.80x |
P/B | 3.22x |
P/CF | -8.40x |
P/FCF | -8.39x |
P/OCF | -8.40x |
PEG | 0.68x |
EV multiple | -7.43x |
About
Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED). The company's portfolio also features VRDN-002, an IGF-1R antibody undergoing Phase 1 clinical evaluation, alongside VRDN-003, a therapeutic antibody also designed to target IGF-1R for TED.
Similar securities
Based on sector and market capitalization
Report issue